Early results of dexamethasone implant, ranibizumab, and triamcinolone in macular edema due to branch retinal vein occlusion.

Abstract

PURPOSE:

To compare the short-term results of the efficacy and safety of dexamethasone intravitreal implant (DEX), ranibizumab (RAN), and intravitreal triamcinolone acetonide (IVTA) in macular edema secondary to branch retinal vein occlusion (BRVO).

METHODS:

One eye each of 32 patients who were treated with intravitreal injections for macular edema secondary to BRVO was studied. This retrospective study included 3 groups. The patients received DEX in group 1 (n = 11), RAN in group 2 (n = 11), and IVTA in group 3 (n = 10). Data were collected before and after the injections at the first and third months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were analyzed statistically.

RESULTS:

The median duration of the follow-up was 3.0 months in overall groups. The BCVA increased significantly in all groups (p = 0.018, p = 0.034, p = 0.014, respectively). The CMT increased significantly in groups 1 and 3 (p = 0.02, p<0.001, respectively), but not in group 2 (p = 0.14). The IOP increased significantly in groups 1 and 3 (p = 0.05, p<0.001, respectively). Antiglaucomatous treatment was required only in group 3. Cataract developed in 2 patients (20%) in group 3 and surgery was required.

CONCLUSIONS:

Although RAN was the safest among the 3 agents, DEX and IVTA reduced CMT more than RAN, while significant improvement was achieved in BCVA in all groups. All 3 agents can be effectively used in the treatment of macular edema due to BRVO.

• Authors: Erhan Yumusak, Nesrin Buyuktortop, Kemal Ornek
• Journal: European journal of ophthalmology (Eur J Ophthalmol) 2016 Jan-Feb Vol. 26 Issue 1 Pg. 54-9 ISSN: 1724-6016 [Electronic] United States
• PMID: 26109021 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Drug Implants
• Glucocorticoids
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Dexamethasone
• Triamcinolone Acetonide
• Ranibizumab

Topics

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (therapeutic use)
• Dexamethasone (administration & dosage)
• Drug Implants
• Female
• Glucocorticoids (administration & dosage)
• Humans
• Intraocular Pressure (drug effects, physiology)
• Intravitreal Injections
• Macula Lutea (pathology)
• Macular Edema (drug therapy, etiology)
• Male
• Middle Aged
• Organ Size
• Ranibizumab (therapeutic use)
• Retinal Vein Occlusion (complications, drug therapy)
• Retrospective Studies
• Tonometry, Ocular
• Treatment Outcome
• Triamcinolone Acetonide (administration & dosage)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (drug effects, physiology)